{"chunk_type":"transcript_chunk","text":"### ğŸ“‹ Overview / TL;DR\n- **ì£¼ì œ:** The Bleeding Patient (Platelets & Hemostasis) - USMLE Step 2 CK High Yield.\n- **í•µì‹¬ êµ¬ë¶„:** Platelet ì¶œí˜ˆ (í”¼ë¶€/ì ë§‰) vs. Factor ì¶œí˜ˆ (ê¹Šì€ ê´€ì ˆ).\n- **ì£¼ìš” ì§ˆí™˜:** Thrombocytopenia, ITP, TTP, HUS, Vitamin K Deficiency.\n- **ì¹˜ëª…ì  ì¡°ì¹˜:** Mixing Studies í•´ì„, TTPì—” PLEX, HUSì—” **Antibiotics ì ˆëŒ€ ê¸ˆì§€**.\n---\n(ì›Œë°ì—… ì—†ì´ ë°”ë¡œ ë³¸ë¡ ìœ¼ë¡œ ë“¤ì–´ê°„ë‹¤ëŠ” ë‚´ìš© í™•ì¸ ì™„ë£Œ! ğŸ”¥)\n---\n### ğŸŒ³ Top-Down Classification: The Bleeding Patient\nìš°ë¦¬ê°€ ì§€ê¸ˆ ì–´ë””ë¥¼ ê³µë¶€í•˜ê³  ìˆëŠ”ì§€ **Big Picture**ë¶€í„° ì¡ê³  ê°‘ì‹œë‹¤.\nPlaintext\n`THE BLEEDING PATIENT (ì¶œí˜ˆ í™˜ì)\nâ”‚\nâ”œâ”€â”€ 1. Primary Hemostasis (Platelets: í˜ˆì†ŒíŒ) ğŸ©¸\nâ”‚   â”‚  * ì¦ìƒ: Mucosal bleeding (ì ë§‰), Petechiae (ì ìƒì¶œí˜ˆ), Epistaxis (ì½”í”¼)\nâ”‚   â”‚\nâ”‚   â”œâ”€â”€ Low Quantity (Thrombocytopenia: ìˆ˜ì  ë¶€ì¡±)\nâ”‚   â”‚   â”œâ”€â”€ Production Failure (ê³µì¥ì´ ë©ˆì¶¤: ê³¨ìˆ˜ ì–µì œ, ë°”ì´ëŸ¬ìŠ¤, ì•Œì½”ì˜¬)\nâ”‚   â”‚   â”œâ”€â”€ Sequestration (ê°€ë‘¬ë‘ : Splenomegaly)\nâ”‚   â”‚   â””â”€â”€ Destruction (ë¶€ìˆ´ë²„ë¦¼: ë§ì´ˆ íŒŒê´´)\nâ”‚   â”‚       â”œâ”€â”€ Immune: ITP (í•­ì²´ê°€ ê³µê²©)\nâ”‚   â”‚       â””â”€â”€ Non-Immune (MAHA): TTP, HUS, DIC (ê°ˆë ¤ë‚˜ê°)\nâ”‚   â”‚\nâ”‚   â””â”€â”€ Low Quality (Function Defect: ê¸°ëŠ¥ ê³ ì¥)\nâ”‚       â””â”€â”€ Uremia, Aspirin, vWD (von Willebrand Disease)\nâ”‚\nâ””â”€â”€ 2. Secondary Hemostasis (Coagulation Factors: ì‘ê³  ì¸ì) ğŸ§¶\n    â”‚  * ì¦ìƒ: Hemarthrosis (ê´€ì ˆ ì¶œí˜ˆ), Deep Muscle Hematoma (ê¹Šì€ ê·¼ìœ¡)\n    â”‚  * Lab: PT/INR (Extrinsic), PTT (Intrinsic)\n    â”‚\n    â”œâ”€â”€ Factor Deficiency (Mixing Study êµì • ë¨)\n    â”‚   â”œâ”€â”€ Hemophilia A (8), B (9)\n    â”‚   â””â”€â”€ Vitamin K Deficiency (2, 7, 9, 10, C, S)\n    â”‚\n    â””â”€â”€ Inhibitors (Mixing Study êµì • ì•ˆ ë¨)\n        â””â”€â”€ Lupus Anticoagulant (Anti-phospholipid Syndrome)`\n---\n# ğŸ©¸ H1: SECTION 3.0 - PLATELETS (The Basics)\n### ğŸšª Doorway Thought (ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤)\n- **ìƒí™©:** íšŒì§„ ë„ëŠ”ë° í™˜ì ì •ê°•ì´ì— **ë°”ëŠ˜ë¡œ ì½•ì½• ì°Œë¥¸ ë“¯í•œ ë¶‰ì€ ì (Petechiae)**ì´ ì«™ ê¹”ë ¤ ìˆìŠµë‹ˆë‹¤.\n- **ì¤‘ìš” í¬ì¸íŠ¸:** í™˜ìê°€ \"ë¬´ë¦ ê´€ì ˆì´ ì•„íŒŒìš”(Deep joint pain)\"ë¼ê³ ëŠ” **ì•ˆ í•´ìš”**.\n- **í•´ì„:** ì´ê±´ ë¬´ì¡°ê±´ **Platelet ë¬¸ì œ**ì…ë‹ˆë‹¤.\n    - **Platelet Defect:** ì ë§‰ ì¶œí˜ˆ, Epistaxis(ì½”í”¼), Hematuria, Petechiae/Purpura.\n    - **Factor Defect (Clotting):** ê¹Šì€ ì¡°ì§ ì¶œí˜ˆ, **Hemarthrosis** (ë¬´ë¦ ê°™ì€ ê´€ì ˆ ì•ˆì— í”¼ê°€ ì°¨ì„œ ë¶“ëŠ” ê²ƒ).\n### ğŸ¥ The Thrombocytopenia Framework (í˜ˆì†ŒíŒ ê°ì†Œì¦ ì ‘ê·¼ë²•)\në¬´ì‘ì • ì™¸ìš°ì§€ ë§ê³ , ë”± **ë‘ ê°€ì§€ ë°”êµ¬ë‹ˆ(Bucket)**ë¡œ ë‚˜ëˆ„ì„¸ìš”:\n### Bucket A: Decreased Production (ê³µì¥ì´ ê³ ì¥ ë‚¨) ğŸ­\n- **Viral Infections:** EBV, Hepatitis C, HIV.\n    - â˜… **Clinical Pearl:** Thrombocytopeniaê°€ **HIVì˜ ìœ ì¼í•œ ì´ˆê¸° ì¦ìƒ**ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¬´ì¡°ê±´ Screen í•˜ì„¸ìš”!\n- **Toxins/Drugs:** Chemotherapy, **Alcohol** (ì•Œì½”ì˜¬ì€ ê³¨ìˆ˜ë¥¼ ì§ì ‘ ì–µì œí•©ë‹ˆë‹¤).\n- **Nutritional:** B12/Folate deficiency (DNA ì¬ë£Œê°€ ì—†ìœ¼ë‹ˆ ëª» ë§Œë“¦).\n- **Congenital:** Fanconi Syndrome (Pancytopenia).\n### Bucket B: Increased Destruction (ë§Œë“¤ì–´ë†¨ëŠ”ë° ë¶€ì„œì§) ğŸ”¨","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-103","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment"]}
{"chunk_type":"transcript_chunk","text":"- **Immune:** ITP, HIT (Heparin Induced), Lupus.\n- **Non-Immune (MAHA):** TTP, HUS, DIC (í˜ˆê´€ ì•ˆì—ì„œ ê°ˆë ¤ ë‚˜ê°).\n- **Sequestration:** **Splenomegaly** (Cirrhosis/Portal Hypertension).\n    - *ê°œë…:* ë¹„ì¥(Spleen)ì€ ê±°ëŒ€í•œ ìŠ¤í€ì§€ì˜ˆìš”. í˜ˆì†ŒíŒì˜ 80-90%ë¥¼ ê°€ë‘¬ë‘˜ ìˆ˜ ìˆì–´ìš”. ìˆ˜ì¹˜ëŠ” ë‚®ê²Œ ì°íˆì§€ë§Œ, í™˜ìëŠ” ë³´í†µ ê´œì°®ìŠµë‹ˆë‹¤.\n### âš ï¸ The Trap: Pseudothrombocytopenia (ê°€ì§œ í˜ˆì†ŒíŒ ê°ì†Œì¦)\n- **ìƒí™©:** ì»´í“¨í„°ëŠ” í˜ˆì†ŒíŒ ìˆ˜ì¹˜ê°€ ë°”ë‹¥ì´ë¼ê³  ë‚œë¦¬ ë‚¬ëŠ”ë°, í™˜ìëŠ” ë„ˆë¬´ ë©€ì©¡í•´ìš”.\n- **ì›ì¸:** **EDTA (ë³´ë¼ìƒ‰ ëšœê»‘ íŠœë¸Œ)**ê°€ í˜ˆì†ŒíŒë¼ë¦¬ ë­‰ì¹˜ê²Œ(Clumping) ë§Œë“¤ì–´ìš”. ê¸°ê³„ëŠ” ì´ ë©ì–´ë¦¬ë¥¼ ì„¸í¬ 1ê°œë¡œ ì„¸ë²„ë¦¬ëŠ” ê±°ì£ .\n- **â˜… Next Best Step:** **Citrate (íŒŒë€ ëšœê»‘)** ë˜ëŠ” Heparin íŠœë¸Œë¡œ ë‹¤ì‹œ ì±„í˜ˆ(Repeat CBC).\n    - í˜¹ì€ Peripheral smearë¥¼ ë´ì„œ ë­‰ì³ìˆëŠ”ì§€ í™•ì¸í•©ë‹ˆë‹¤.\n---\n# ğŸ§¬ H1: SECTION 3.1 - HEMOSTASIS (Coagulation)\n### ğŸšª Doorway Thought\n- **ìƒí™©:** í™˜ì AëŠ” ë¬´ë¦ì„ ì‚´ì§ ì°§ì—ˆëŠ”ë° í‰í‰ ë¶€ìŒ (Hemarthrosis). í™˜ì BëŠ” ë©´ë„í•˜ë‹¤ ë² ì˜€ëŠ”ë° 20ë¶„ì§¸ í”¼ê°€ ì•ˆ ë©ˆì¶¤.\n- **Labs:** PT í˜¹ì€ PTTê°€ ë†’ê²Œ ë‚˜ì˜´(Elevated).\n### ğŸ§ª The Fork in the Road: Mixing Study (ë¯¹ì‹± ìŠ¤í„°ë””)\nPTT/PTê°€ ë–´ì„ ë•Œ ê°€ì¥ ë¨¼ì € í•´ì•¼ í•  **First Step**ì…ë‹ˆë‹¤.\n- **ë°©ë²•:** í™˜ìì˜ í˜ˆì¥(Plasma) 1 + ì •ìƒì¸ì˜ í˜ˆì¥ 1ì„ ì„ìŠµë‹ˆë‹¤.\n- **ë…¼ë¦¬:** ìš°ë¦¬ ëª¸ì€ ì‘ê³  ì¸ìê°€ **50%**ë§Œ ìˆì–´ë„ ì •ìƒì ìœ¼ë¡œ í”¼ê°€ êµ³ìŠµë‹ˆë‹¤.\n| **ê²°ê³¼ (Result)** | **í•´ì„ (Interpretation)** | **ì˜ˆì‹œ (Examples)** |\n| --- | --- | --- |\n| **Corrects to Normal (ì •ìƒí™” ë¨)** | **Factor Deficiency (ë¶€ì¡±)** | Hemophilia A/B, Vit K Def. (ì •ìƒ í˜ˆì¥ì´ ë¶€ì¡±ë¶„ì„ ì±„ì›Œì¤Œ). |\n| **Fails to Correct (êµì • ì•ˆ ë¨)** | **Inhibitor Present (ë°©í•´ê¾¼)** | Lupus Anticoagulant, Factor 8 Inhibitor. (ë°©í•´ê¾¼ì´ ë„£ì–´ì¤€ ì •ìƒ í˜ˆì¥ê¹Œì§€ ê³µê²©í•¨). |\n# ğŸ¥¦ H1: SECTION 3.1.1 - VITAMIN K DEFICIENCY\n### ğŸ§  Pathophysiology\n- Vitamin KëŠ” **Gamma-Carboxylation**ì˜ í•„ìˆ˜ ì¡°ìˆ˜(Co-factor)ì…ë‹ˆë‹¤.\n- í™œì„± ì¸ì: **2, 7, 9, 10, Protein C, Protein S**.\n- **ê³µê¸‰ì›:** ìì±„ì†Œ(Leafy greens) ğŸ¥¬ & **ì¥ë‚´ ì„¸ê· (Gut Bacteria)** ğŸ¦ .\n### ğŸ‘¶ Scenario A: The Newborn Bleed (ì‹ ìƒì•„ ì¶œí˜ˆ)\n- **Vignette:** ìƒí›„ 4ì¼ ëœ ì•„ê¸°. ë°°ê¼½(Umbilical stump)ì—ì„œ í”¼ê°€ ê³„ì† ë‚¨.\n- **ì´ìœ :** ì‹ ìƒì•„ëŠ” **Sterile Gut (ë¬´ê·  ìƒíƒœ)**ìœ¼ë¡œ íƒœì–´ë‚¨ -> ë°•í…Œë¦¬ì•„ê°€ ì—†ìœ¼ë‹ˆ Vit K ê³µì¥ ê°€ë™ ë¶ˆê°€ + íƒœë°˜ í†µê³¼ ì˜ ì•ˆë¨ + ëª¨ìœ ì— Vit K ì ìŒ.\n- **í•©ë³‘ì¦:** **Intracranial Hemorrhage** (ë‡Œì¶œí˜ˆ... ì¹˜ëª…ì ì…ë‹ˆë‹¤).\n- **â˜… Gold Standard Prevention:** íƒœì–´ë‚˜ìë§ˆì **IM Vitamin K** ì£¼ì‚¬ (í‘œì¤€ ì¹˜ë£Œ).\n    - *ì‹œí—˜ ë¬¸ì œ:* ì§‘ì—ì„œ ì¶œì‚°(Home birth)í•´ì„œ ì˜ë£Œ ì²˜ì¹˜ ëª» ë°›ì€ ì•„ê¸° -> ë¬´ì¡°ê±´ Vit K ê²°í• ì˜ì‹¬!\n### ğŸ’Š Scenario B: The \"Sick Liver\" Trap (ê°„ì§ˆí™˜/í•­ìƒì œ)\n- **í™˜ì:** Cirrhosis í™˜ì í˜¹ì€ ICUì—ì„œ ì˜¤ë«ë™ì•ˆ **Broad-Spectrum Antibiotics** ì“°ëŠ” í™˜ì.\n- **ê¸°ì „:** í•­ìƒì œê°€ ì¥ë‚´ ì„¸ê· (Flora)ì„ ë‹¤ ì£½ì„ -> Vit K ìƒì‚° ì¤‘ë‹¨ -> ì¶œí˜ˆ.\n- **Lab:** **PT/INRì´ ê°€ì¥ ë¨¼ì € ì˜¤ë¦„** (Factor 7ì˜ ë°˜ê°ê¸°ê°€ ì œì¼ ì§§ê¸° ë•Œë¬¸).","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-123","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"---\n# ğŸ›¡ï¸ H1: SECTION 3.1.2 - ITP (Immune Thrombocytopenic Purpura)\n### ğŸšª Doorway Thought\n- **Vignette:** ê±´ê°•í•˜ë˜ 5ì„¸ ì•„ì´ (í˜¹ì€ ì Šì€ ì—¬ì„±). 2ì£¼ ì „ì— ê°ê¸° ê¸°ìš´ ìˆì—ˆëŠ”ë° ë‹¤ ë‚˜ìŒ. ê·¼ë° ê°‘ìê¸° ë‹¤ë¦¬ì— ë¹¨ê°„ ì (Petechiae)ì´ ì«™ ì˜¬ë¼ì˜´.\n- **Pathophysiology:** ìê°€ë©´ì—­ ê³µê²©. IgG í•­ì²´ê°€ í˜ˆì†ŒíŒì˜ **GPIIb/IIIa** ìˆ˜ìš©ì²´ì— ë“¤ëŸ¬ë¶™ìŒ. ë¹„ì¥(Spleen)ì˜ Macrophageê°€ ì´ 'ì–‘ë… ëœ' í˜ˆì†ŒíŒì„ ì¡ì•„ë¨¹ìŒ.\n### ğŸ” Diagnosis (ì§„ë‹¨)\n- **ë°°ì œ ì§„ë‹¨ (Diagnosis of Exclusion).**\n- **Labs:** Isolated Thrombocytopenia (í˜ˆì†ŒíŒë§Œ ë‚®ìŒ). Hb, WBC, PT/PTTëŠ” ë‹¤ ì •ìƒì´ì–´ì•¼ í•¨.\n- **Smear:** í˜ˆì†ŒíŒ ìˆ˜ëŠ” ì ì§€ë§Œ, í¬ê¸°ê°€ ì—„ì²­ í¼ **Megathrombocytes** (ê³¨ìˆ˜ê°€ ì—´ì‹¬íˆ ì¼í•˜ê³  ìˆë‹¤ëŠ” ì¦ê±°).\n- ì„±ì¸ì—ì„œëŠ” HIV, Hep C ë°˜ë“œì‹œ ê²€ì‚¬í•´ì•¼ë¨!\n### ğŸ’Š Management (ì¹˜ë£Œ ì•Œê³ ë¦¬ì¦˜ - ì¤‘ìš”!)\n*ì¹˜ë£Œë¥¼ ì‹œì‘í•˜ëŠ” ê¸°ì¤€ì´ ì—„ê²©í•©ë‹ˆë‹¤.*\n**1. Children (ì†Œì•„):**\n- **ì„ìƒ:** ëŒ€ë¶€ë¶„ ì €ì ˆë¡œ ì¢‹ì•„ì§ (Self-limiting).\n- **â˜… Next Best Step:** í”¼ë¶€ ì¦ìƒë§Œ ìˆë‹¤ë©´ **Observation (ê²½ê³¼ ê´€ì°°)**.\n- **Treat if:** ì ë§‰ ì¶œí˜ˆ(Active mucosal bleeding)ì´ ìˆì„ ë•Œë§Œ.\n    - **Rx:** IVIG or Glucocorticoids.\n**2. Adults (ì„±ì¸):**\n- **Platelets > 30,000 & ì¶œí˜ˆ ì—†ìŒ:** Observe.\n- **Platelets < 30,000 OR ì¶œí˜ˆ ìˆìŒ:** TREAT.\n    - **First Line:** **Corticosteroids** (Prednisone) í˜¹ì€ **IVIG** (ìˆ˜ì¹˜ ë¹¨ë¦¬ ì˜¬ë ¤ì•¼ í•  ë•Œ).\n    - **Refractory (ì•ˆ ë“¤ìœ¼ë©´):** Rituximab í˜¹ì€ **Splenectomy** (íŒŒê´´ ì¥ì†Œì¸ ë¹„ì¥ ì œê±°).\n    - **Adjunct:** RhoGAM (Anti-D) *ë‹¨, í™˜ìê°€ Rh+ì´ê³  ë¹„ì¥ì´ ìˆì„ ë•Œë§Œ* (ë¹„ì¥ì´ í˜ˆì†ŒíŒ ëŒ€ì‹  ì í˜ˆêµ¬ë¥¼ ë¨¹ê²Œ ì†ì´ëŠ” ì›ë¦¬).\n---\n# ğŸ•¸ï¸ H1: SECTION 3.1.3 - TTP (Thrombotic Thrombocytopenic Purpura)\n### â˜ ï¸ The Mechanism (ì§„ì§œ ë¬´ì„œìš´ ë³‘, High Yield)\n- **ê²°í•:** **ADAMTS13** (vWFë¥¼ ì ì ˆí•œ í¬ê¸°ë¡œ ì˜ë¼ì£¼ëŠ” ê°€ìœ„ íš¨ì†Œ).\n- **ê²°ê³¼:** ê°€ìœ„ê°€ ì—†ìœ¼ë‹ˆ vWFê°€ ì—„ì²­ ê¸¸ê²Œ ì´ì–´ì§(Multimers) -> í˜ˆê´€ ì•ˆì— ëˆì í•œ ê±°ë¯¸ì¤„(Microthrombi) ì¹¨ -> í˜ˆì†ŒíŒì´ ê±°ê¸° ê±¸ë ¤ì„œ ì†Œëª¨ë¨(ìˆ˜ì¹˜ â†“) -> ì í˜ˆêµ¬ê°€ ì§€ë‚˜ê°€ë‹¤ ì°¢ì–´ì§ (**Schistocytes**).\n- **ë¹„ìœ :** \"ê°•ì²  ì™€ì´ì–´ë¡œ ëœ ê±°ë¯¸ì¤„ ì‚¬ì´ë¥¼ í†µê³¼í•˜ëŠ” ê²ƒê³¼ ê°™ì•„ìš”.\"\n- PT, aPTT normal (cascadeí™œì„±í™”ì•ˆë¨) (vs DIC)\n- shictocytes\n- LDH â†‘ , haptoglobin â†“\n- coombs negative -\n### ğŸš© The \"FAT RN\" Pentad (5ëŒ€ ì¦ìƒ)\nì§„ë‹¨ì„ ìœ„í•´ ê¼­ ì™¸ì›Œì•¼ í•©ë‹ˆë‹¤ (ë‹¤ ìˆì„ í•„ìš”ëŠ” ì—†ì§€ë§Œ PentadëŠ” í´ë˜ì‹!).\n1. **F**ever\n2. **A**nemia (Microangiopathic Hemolytic Anemia - MAHA)\n3. **T**hrombocytopenia (í˜ˆì†ŒíŒ ë‹¤ ì¨ë²„ë¦¼)\n4. **R**enal Failure (Creatinine ìƒìŠ¹) (ì£¼ì¦ìƒì´ ì•„ë‹˜! Renal failureê°€ ì£¼ì¦ìƒì´ë©´ HUS)\n5. **N**euro Symptoms (í˜¼ë€, ë‘í†µ, ë‡Œì¡¸ì¤‘, ë°œì‘) â˜… **ê°€ì¥ ë‘ë“œëŸ¬ì§€ëŠ” íŠ¹ì§• (DOMINANT FEATURE)**","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-143","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"### âš ï¸ Management (ì‚¶ê³¼ ì£½ìŒì˜ ê²½ê³„)\n- **â˜… Next Best Step:** **Plasma Exchange (PLEX)**.\n    - *ì´ìœ ?* ADAMTS13 í•­ì²´ë¥¼ ì œê±°í•˜ê³ , ì •ìƒ íš¨ì†Œë¥¼ ë„£ì–´ì¤ë‹ˆë‹¤.\n- **HARD STOP / CONTRAINDICATION:** **NEVER GIVE PLATELETS! (í˜ˆì†ŒíŒ ìˆ˜í˜ˆ ì ˆëŒ€ ê¸ˆì§€)** ğŸš«\n    - *ì´ìœ ?* \"ë¶ˆë‚œ ì§‘ì— ê¸°ë¦„ ë¶“ê¸°\"ì…ë‹ˆë‹¤. í˜ˆì†ŒíŒ ë„£ì–´ì£¼ë©´ í˜ˆì „(Thrombi)ë§Œ ë” ë§Œë“¤ì–´ì„œ í™˜ì ìƒíƒœ ì•…í™”ë©ë‹ˆë‹¤.\n---\n# ğŸ” H1: SECTION 3.1.4 - HUS (Hemolytic Uremic Syndrome)\n### ğŸšª Doorway Thought\n- **Vignette:** ì•„ì´ê°€ BBQ íŒŒí‹° ê°€ì„œ **ëœ ìµì€ í–„ë²„ê±°** ë¨¹ìŒ. í”¼ ì„ì¸ ì„¤ì‚¬(Bloody diarrhea) í•¨. ì¼ì£¼ì¼ ë’¤ -> í”¼ê³¤í•´í•˜ê³  ì†Œë³€ì´ ì•ˆ ë‚˜ì˜´(Oliguria).\n- **Bug:** E. Coli O157:H7 (Shiga-like toxin).\n### ğŸ” Pathophysiology\n- TTPë‘ ë¹„ìŠ·í•¨ (MAHA + Thrombocytopenia) í•˜ì§€ë§Œ...\n- **íƒ€ê¹ƒ:** ë…ì†Œ(Toxin)ê°€ ë‡Œë³´ë‹¤ëŠ” **ì‹ ì¥(Kidney)** ìˆ˜ìš©ì²´ë¥¼ ì¢‹ì•„í•¨.\n- **Dominant Feature:** **Renal Failure** (BUN/Creatinine íŒ íŠ).\n- **ëŒ€ì¡°:** TTP = Neuro ìœ„ì£¼ / HUS = Kidney ìœ„ì£¼.\n### ğŸ’Š Management\n- **ì£¼ìš” ì¹˜ë£Œ:** **Supportive Care** (ìˆ˜ì•¡, í•„ìš”í•˜ë©´ íˆ¬ì„ Dialysis).\n- **CONTRAINDICATION:** **NO ANTIBIOTICS** & **NO ANTI-MOTILITY** (ì§€ì‚¬ì œ ê¸ˆì§€).\n    - *ì´ìœ ?* ë°•í…Œë¦¬ì•„ë¥¼ ì£½ì´ë©´ ë…ì†Œê°€ í•œêº¼ë²ˆì— ìŸì•„ì ¸ ë‚˜ì™€ì„œ(Herxheimer-like reaction) ì‹ ì¥ì´ ì™„ì „íˆ ë§ê°€ì§‘ë‹ˆë‹¤. ê·¸ëƒ¥ ë˜¥ìœ¼ë¡œ ë°°ì¶œë˜ê²Œ ë†”ë‘¬ì•¼ í•´ìš”.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-163","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# âš¡ Rapid Fire Recap (ìš”ì•½ í…Œì´ë¸”)\n| **ì§ˆí™˜ (Condition)** | **ê¸°ì „ (Mechanism)** | **í•µì‹¬ Vignette íŠ¹ì§•** | **ì¹˜ë£Œ / Pearl (Tx)** |\n| --- | --- | --- | --- |\n| **Pseudothrombocytopenia** | Lab ì˜¤ë¥˜ (Clumping) | ìˆ˜ì¹˜ëŠ” ë‚®ì€ë° í™˜ìëŠ” ë©€ì©¡ | **Blue Tube (Citrate)ë¡œ ì¬ê²€** |\n| **Vitamin K Def.** | Factor 2,7,9,10,C,S ë¶€ì¡± | ì‹ ìƒì•„ ì¶œí˜ˆ, ì¥ê¸° í•­ìƒì œ ì‚¬ìš© | **IM Vit K**, ê¸‰í•˜ë©´ FFP |\n| **ITP** | ìê°€ë©´ì—­ (Anti-GPIIb/IIIa) | Isolated Low Platelets, ê°ê¸° í›„ | **Steroids/IVIG** (<30k ì¼ ë•Œ). **HIV/Hep C ë°°ì œ**. |\n| **TTP** | ADAMTS13 ê²°í• | **FAT RN** (Neuro ì¦ìƒ), Schistocytes | **PLEX** ì¦‰ì‹œ ì‹œí–‰. **Platelets ê¸ˆì§€!** |\n| **HUS** | Shiga Toxin (E. Coli) | Bloody Diarrhea + **Renal Failure** | **Supportive**. **Antibiotics ì ˆëŒ€ ê¸ˆì§€!** |\n| **Mixing Study** | Lab ë…¼ë¦¬ | PTT ìƒìŠ¹ ì‹œ ì‹œí–‰ | **Corrects** = ê²°í•. **Fails** = ì–µì œì œ(Inhibitor). |\n| **Massive Transfusion** | í¬ì„ë¨ (Dilutional) | PRBC 10íŒ© ì´ìƒ ìˆ˜í˜ˆ ì‹œ | **FFP & Platelets** ê°™ì´ ì¤˜ë¼ (1:1:1 ë¹„ìœ¨) |\n- **Splenic Sequestration:** \"ì¦ìƒ ì—†ëŠ”\" í˜ˆì†ŒíŒ ê°ì†Œ í™˜ìì—ì„œ ê°„ê²½í™”(Cirrhosis)ë‚˜ ë¹„ì¥ë¹„ëŒ€(Splenomegaly) ê¼­ í™•ì¸í•˜ì„¸ìš”.\n- **TTP vs DIC:** TTPëŠ” Coags(PT/PTT)ê°€ **ì •ìƒ**ì…ë‹ˆë‹¤. DICëŠ” Coagsê°€ **ìƒìŠ¹**í•©ë‹ˆë‹¤. ì´ê²Œ ê°ë³„ í¬ì¸íŠ¸!\n- **Confidence:** ì˜¤ë””ì˜¤ ë‚´ìš©ì„ 100% ë°˜ì˜í•˜ì—¬ ì‘ì„±í–ˆìŠµë‹ˆë‹¤.\n---\n**\"FAT RN\" 5ëŒ€ ì¦ìƒì„ ì´ìš©í•´ì„œ USMLE ìŠ¤íƒ€ì¼ì˜ ì—°ìŠµ ë¬¸ì œë¥¼ í•˜ë‚˜ ë§Œë“¤ì–´ ë“œë¦´ê¹Œìš”?**\n### ğŸ“‹ Overview: The Hemostasis Battlefield (TL;DR)\n| **Topic** | **Key Concept (Mental Model)** | **Critical \"Do Not Miss\"** |\n| --- | --- | --- |\n| **MAHA** | **Razor Wire** (Micro-clots shred RBCs) ğŸ©¸ğŸ”ª | Look for **Schistocytes** (Helmet cells) on smear. |\n| **TTP** | **Missing Scissors** (ADAMTS13 deficiency) âœ‚ï¸ğŸš« | **NEVER give platelets** (Fuel to fire). Rx: Plasma Exchange (PEX). |\n| **HUS** | **The Antibiotic Trap** (E. coli toxin bomb) ğŸ”ğŸ’£ | **NO Antibiotics** for bloody diarrhea in kids (causes renal failure). |\n| **ITP** | **Mistaken Identity** (Antibodies eat platelets) ğŸ·ï¸ğŸ½ï¸ | Diagnosis of exclusion. **Test for HIV/Hep C**. |\n| **Mixing Study** | **The Logic Puzzle** (Deficiency vs. Inhibitor) ğŸ§© | Corrects = Deficiency. No correction = Inhibitor. |\n| **DIC** | **The Consumer** (Everything used up) ğŸ“‰ | Acute = Bleeding (Sepsis). Chronic = Clotting (Cancer). |\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-174","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"### ğŸŒ³ Top-down Classification: Hemostasis Disorders\nPlaintext\n#\n`HEMOSTASIS (Stopping the Bleed)\nâ”‚\nâ”œâ”€â”€ Primary Hemostasis (Platelet Plug) â†’ \"Mucosal Bleeding\" (Gums, Nose, Menses)\nâ”‚   â”œâ”€â”€ Destruction/Consumption (Low Count)\nâ”‚   â”‚   â”œâ”€â”€ Immune Mediated: ITP (Antibodies vs Platelets)\nâ”‚   â”‚   â””â”€â”€ Non-Immune (MAHA - The Razor Wire)\nâ”‚   â”‚       â”œâ”€â”€ TTP (ADAMTS13 deficiency â†’ CNS symptoms)\nâ”‚   â”‚       â”œâ”€â”€ HUS (E. coli toxin â†’ Renal failure)\nâ”‚   â”‚       â””â”€â”€ DIC (Acute/Sepsis â†’ Consumptive Coagulopathy)\nâ”‚   â”‚\nâ”‚   â””â”€â”€ Dysfunction (Normal Count, Bad Quality)\nâ”‚       â”œâ”€â”€ Von Willebrand Disease (Bad glue)\nâ”‚       â””â”€â”€ Uremia (Kidney failure makes platelets \"drunk\")\nâ”‚\nâ””â”€â”€ Secondary Hemostasis (Coagulation Cascade) â†’ \"Deep Bleeding\" (Joints, Muscles)\n    â”œâ”€â”€ Factor Deficiency (Mixing Study Corrects)\n    â”‚   â”œâ”€â”€ Hemophilia A (Factor 8)\n    â”‚   â”œâ”€â”€ Hemophilia B (Factor 9)\n    â”‚   â””â”€â”€ Vitamin K Deficiency (Factors 2, 7, 9, 10)\n    â”‚\n    â””â”€â”€ Factor Inhibitors (Mixing Study FAILS to Correct)\n        â”œâ”€â”€ Acquired Hemophilia (Antibodies vs Factor 8)\n        â””â”€â”€ Lupus Anticoagulant (Paradox: Lab Bleed, Body Clot)`\n---\n### ğŸ–¼ï¸ Big Picture: The \"Goldilocks\" System ğŸ»ğŸ‘±â€â™€ï¸\n**Context & Pathophysiology:**\ní˜ˆì•¡(Blood)ì€ ì•¡ì²´(Liquid) ìƒíƒœë¡œ ì „ì‹  60,000ë§ˆì¼ì˜ í˜ˆê´€ì„ ìˆœí™˜í•˜ë©° ì‚°ì†Œë¥¼ ê³µê¸‰í•´ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ í˜ˆê´€ì— êµ¬ë©(Cut, Bruise)ì´ ìƒê¸°ëŠ” ìˆœê°„, ê·¸ ì¦‰ì‹œ! í•´ë‹¹ ë¶€ìœ„ë§Œ! ê³ ì²´(Solid)ë¡œ ë³€í•´ì•¼ í•©ë‹ˆë‹¤.\n- **Too Much Clotting:** Stroke, PE (Pulmonary Embolism).\n- **Too Little Clotting:** ì¢…ì´ì—ë§Œ ë² ì—¬ë„ ê³¼ë‹¤ì¶œí˜ˆë¡œ ì‚¬ë§(Bleed to death).\n- **Margin for Error:** Effectively ZERO.\nì˜¤ëŠ˜ì˜ ì£¼ì œëŠ” ì´ ë°¸ëŸ°ìŠ¤ê°€ ë¬´ë„ˆì¡Œì„ ë•Œ ë°œìƒí•˜ëŠ” **\"Unintended Consequences (ì˜ë„ì¹˜ ì•Šì€ ê²°ê³¼ë“¤)\"**ì…ë‹ˆë‹¤.\n---\n# H1: The Microangiopathic Hemolytic Anemias (MAHA) ğŸ”ªğŸ©¸\n### H2: The Concept of \"Razor Wire\"\ní˜ˆê´€(Highways)ì€ ì›ë˜ ë§¤ë„ëŸ½ê²Œ í¬ì¥ë˜ì–´ ìˆì–´ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ MAHAì—ì„œëŠ” í˜ˆê´€ ë²½ì— ë¬¸ì œê°€ ìƒê²¨ ë¯¸ì„¸í•œ í˜ˆì „(Micro-clots)ë“¤ì´ í˜•ì„±ë©ë‹ˆë‹¤. ì´ í˜ˆì „ë“¤ì´ ë§ˆì¹˜ **\"Razor Wire (ì² ì¡°ë§)\"**ì²˜ëŸ¼ ì‘ìš©í•©ë‹ˆë‹¤.\n- **RBC Fate:** ì í˜ˆêµ¬ê°€ ì´ ì¢ì€ í‹ˆì„ ì§€ë‚˜ê°€ë ¤ë‹¤ ì°¢ê²¨ë²„ë¦¼(Shearing).\n- **Result:** **Schistocytes** (Helmet cells, Burrs, Fragments) visible on the slide.\n- **Core Logic:** í˜ˆì†ŒíŒ(Platelet)ë“¤ì´ ì´ ë¯¸ì„¸ í˜ˆì „ì„ ë§Œë“œëŠë¼ ë‹¤ ì†Œëª¨ë˜ì–´ **Thrombocytopenia**(í˜ˆì†ŒíŒ ê°ì†Œ)ê°€ ë°œìƒí•˜ê³ , ì í˜ˆêµ¬ëŠ” íŒŒê´´ë˜ì–´ **Anemia**(ë¹ˆí˜ˆ)ê°€ ë°œìƒí•©ë‹ˆë‹¤.\n---\n### H2: TTP (Thrombotic Thrombocytopenic Purpura) - The Missing Scissors âœ‚ï¸\n**ğŸšª Vignette Anchor:** í™˜ìê°€ ì—´ì´ ë‚˜ê³ , í˜¼ë€ìŠ¤ëŸ¬ì›Œí•˜ë©°(Confusion/Neuro sx), ë©ì´ ë“¤ì–´ì„œ ì™”ëŠ”ë° ì½©íŒ¥ ìˆ˜ì¹˜ë„ ì•½ê°„ ì´ìƒí•˜ë‹¤. (Pentad: Fever, Anemia, Thrombocytopenia, Renal, **Neuro**)","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-184","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"**1. Mechanism: The Sticky Tape Problem**\n- **vWF (von Willebrand Factor):** í˜ˆê´€ ë²½ì´ ë‹¤ì³¤ì„ ë•Œ í˜ˆì†ŒíŒì„ ë¶™ì—¬ì£¼ëŠ” \"Sticky Tape\"ì…ë‹ˆë‹¤. ì›ë˜ ëª¸ì—ì„œ ìƒì„±ë  ë•ŒëŠ” ì—„ì²­ë‚˜ê²Œ ê¸´(Ultra-long) í˜•íƒœë¡œ ë‚˜ì˜µë‹ˆë‹¤.\n- **ADAMTS13 (The Scissors):** ì´ íš¨ì†ŒëŠ” ë„ˆë¬´ ê¸´ vWF í…Œì´í”„ë¥¼ ì ì ˆí•œ í¬ê¸°ë¡œ ì˜ë¼ì£¼ëŠ” ê°€ìœ„ ì—­í• ì„ í•©ë‹ˆë‹¤.\n- **Pathology:** TTPì—ì„œëŠ” **ADAMTS13 (ê°€ìœ„)**ê°€ ì—†ìŠµë‹ˆë‹¤ (Auto-antibody ë“±ì— ì˜í•´).\n- **Result:** ìë¥´ì§€ ì•Šì€ ì—„ì²­ë‚˜ê²Œ ê¸´ ëˆì í•œ í…Œì´í”„(Long vWF strands)ê°€ í˜ˆê´€ì„ ë– ë‹¤ë‹ˆë‹¤ê°€ \"ê·¸ë¬¼(Net)\"ì²˜ëŸ¼ ì‘ìš©í•˜ì—¬ ì§€ë‚˜ê°€ëŠ” í˜ˆì†ŒíŒë“¤ì„ ë‹¤ ì¡ì•„ë²„ë¦½ë‹ˆë‹¤. â†’ ì „ì‹ ì ì¸ Micro-clots í˜•ì„±.\n**ğŸš¨ Critical Clinical Dilemma**\n- **The Trap:** í˜ˆì†ŒíŒ ìˆ˜ì¹˜ê°€ ë‚®ë‹¤ê³  í•´ì„œ ìˆ˜í˜ˆí•˜ë©´?\n- **Effect:** **Adding Fuel to the Fire.** ğŸ”¥ ë¶ˆ ë‚œ ì§‘ì— ê¸°ë¦„ ë¶“ê¸°ì…ë‹ˆë‹¤. ë„£ì–´ì¤€ í˜ˆì†ŒíŒë“¤ì´ ê·¸ë¬¼ì— ë” ê±¸ë ¤ì„œ í˜ˆì „ì„ ë” ë§ì´ ë§Œë“­ë‹ˆë‹¤. Stroke/Heart Attack ìœ ë°œ ê°€ëŠ¥.\n**â˜… Gold Standard Treatment:**\n- **Plasma Exchange (PEX):** í™˜ìì˜ ë‚˜ìœ í˜ˆì¥(í•­ì²´ê°€ ìˆëŠ”)ì„ ë¹¼ë‚´ê³ , **Donor Plasma (Fresh Scissors âœ‚ï¸ê°€ ë“¤ì–´ìˆëŠ”)**ë¥¼ ë„£ì–´ì£¼ëŠ” ê²ƒ.\n- **â˜… Contraindication:** **Do NOT give Platelets!**\n---\n### H2: HUS (Hemolytic Uremic Syndrome) - The Antibiotic Trap ğŸ”ğŸ’Š\n**ğŸšª Vignette Anchor:** ì•„ì´ê°€ ëœ ìµì€ í–„ë²„ê±°(Undercooked burger)ë¥¼ ë¨¹ê³  ë©°ì¹  ë’¤ **Bloody Diarrhea**ë¥¼ í•˜ë”ë‹ˆ ì†Œë³€ì´ ì•ˆ ë‚˜ì˜¨ë‹¤(Renal Failure).\n**1. Mechanism: The Dirty Bomb**\n- **Trigger:** **E. coli O157:H7**. ì´ ë°•í…Œë¦¬ì•„ëŠ” ê·¸ì € ê· ì´ ì•„ë‹ˆë¼ **\"Shiga-like toxin\"**ì´ë¼ëŠ” ë…ì†Œë¥¼ ê°€ë“ í’ˆê³  ìˆëŠ” ì»¨í…Œì´ë„ˆ(Container)ì…ë‹ˆë‹¤.\n- **Target:** ì´ ë…ì†ŒëŠ” íŠ¹íˆ **Kidney (ì‹ ì¥)** í˜ˆê´€ì„ ê³µê²©í•˜ì—¬ ì°¢ì–´ë²„ë¦½ë‹ˆë‹¤(Shreds lining). â†’ Micro-clots â†’ Kidney Failure.\n**ğŸš¨ The Antibiotic Trap (USMLE High Yield)**\n- **Instinct:** \"ì„¸ê·  ê°ì—¼ì´ë‹ˆê¹Œ í•­ìƒì œë¥¼ ì¨ì„œ ê· ì„ ì£½ì´ì!\" (Infection = Antibiotics logic).\n- **Reality:** í•­ìƒì œê°€ ê· ì„ ê³µê²©í•˜ë©´, ê· ì´ ì£½ìœ¼ë©´ì„œ í„°ì§ˆ ë•Œ ê°€ì§€ê³  ìˆë˜ **Toxin Bomb**ë¥¼ í•œêº¼ë²ˆì— ë°©ì¶œí•©ë‹ˆë‹¤.\n- **Result:** ì—„ì²­ë‚œ ì–‘ì˜ ë…ì†Œê°€ ì‹ ì¥ì„ ê°•íƒ€í•˜ì—¬ HUSë¥¼ ìœ ë°œí•˜ê±°ë‚˜ ì•…í™”ì‹œí‚µë‹ˆë‹¤.\n**â˜… Next Best Step:**\n- **Supportive Care:** Hydration (ìˆ˜ì•¡ ê³µê¸‰), Dialysis if needed.\n- **â˜… Contraindication:** **NO Antibiotics**, **NO Anti-motility agents** (Imodium ë“±, ë…ì†Œ ë°°ì¶œì„ ë§‰ìŒ).\n---\n# H1: ITP (Immune Thrombocytopenia) - The Innocent Bystander ğŸ·ï¸ğŸ˜¢\n### H2: Mechanism & Diagnosis\n**ğŸšª Vignette Anchor:** ê±´ê°•í•´ ë³´ì´ëŠ” ì—¬ì„±ì´ ì–‘ì¹˜í•  ë•Œ í”¼ê°€ ë‚˜ê±°ë‚˜ ë‹¤ë¦¬ì— ì‘ì€ ë¶‰ì€ ë°˜ì (Petechiae)ì´ ìƒê²¨ì„œ ì™”ë‹¤. ë‹¤ë¥¸ ìˆ˜ì¹˜ëŠ” ë‹¤ ì •ìƒì¸ë° í˜ˆì†ŒíŒë§Œ ë‚®ë‹¤.\n**1. Mechanism: Mistaken Identity**","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-204","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"- ë©´ì—­ ì²´ê³„ê°€ í˜ˆì†ŒíŒì„ ì™¸ë¶€ ì¹¨ì…ìë¡œ ì˜¤ì¸í•˜ì—¬ **\"Eat Me\"** íƒœê·¸(Antibody)ë¥¼ ë¶™ì…ë‹ˆë‹¤.\n- **Spleen (ë¹„ì¥):** íƒœê·¸ëœ í˜ˆì†ŒíŒì„ ë³´ê³  \"í•„í„°\" ì—­í• ë¡œì„œ ì¡ì•„ë¨¹ìŠµë‹ˆë‹¤. (Splenic Macrophage consumption).\n**2. Diagnosis of Exclusion**\n- ITPëŠ” ë‹¤ë¥¸ ì›ì¸ì´ ì—†ì„ ë•Œ ë¶™ì´ëŠ” ì§„ë‹¨ëª…ì…ë‹ˆë‹¤.\n- **â˜… Sentinel Event (Must Do):** ë°˜ë“œì‹œ **HIV**ì™€ **Hepatitis C** ê²€ì‚¬ë¥¼ í•´ì•¼ í•©ë‹ˆë‹¤. ì´ ë°”ì´ëŸ¬ìŠ¤ë“¤ì´ ì´ˆê¸° ì¦ìƒìœ¼ë¡œ ITPì²˜ëŸ¼ ë‚˜íƒ€ë‚  ìˆ˜ ìˆìŠµë‹ˆë‹¤. (5-10% of patients).\n**3. Treatment Strategy: \"Less is More\"**\n- í˜ˆì†ŒíŒ ìˆ˜ì¹˜ê°€ **>30,000**ì´ê³  ì¶œí˜ˆì´ ì—†ë‹¤ë©´? â†’ **Observe** (ì•„ë¬´ê²ƒë„ í•˜ì§€ ì•ŠìŒ).\n- **Treatment:**\n    - **Steroids:** ë©´ì—­ ë°˜ì‘ ì–µì œ.\n    - **IVIG (Intravenous Immunoglobulin):** ë¹„ì¥(Spleen)ì—ê²Œ ë˜ì ¸ì£¼ëŠ” \"ë¯¸ë¼(Distraction)\"ì…ë‹ˆë‹¤. ë¹„ì¥ì´ IVIGë¥¼ ë¨¹ëŠë¼ ë°”ë¹ ì„œ í˜ˆì†ŒíŒì„ ì•ˆ ê±´ë“œë¦¬ê²Œ í•¨.\n---\n# H1: The Coagulation Cascade & The Mixing Study Logic ğŸ§©\n### H2: Hemophilia vs. Inhibitors\n**ğŸšª Vignette Anchor:** ì–´ë¦° ì•„ì´ê°€ ê±·ê¸° ì‹œì‘í•˜ë©´ì„œ ìê¾¸ ë„˜ì–´ì ¸ ë¬´ë¦ì´ ì—„ì²­ë‚˜ê²Œ ë¶“ëŠ”ë‹¤(Hemarthrosis). PTTê°€ ì—°ì¥ë˜ì–´ ìˆë‹¤.\n**1. Clinical Picture: Joint vs. Mucosal**\n- **Platelet issue:** Skin, Mucosa bleeding (Petechiae).\n- **Factor issue (Hemophilia):** **Deep bleeding** (Joints, Muscles). í”¼ê°€ ê´€ì ˆ ë‚´ì˜ ì—°ê³¨ê³¼ ë¼ˆë¥¼ íŒŒê´´í•©ë‹ˆë‹¤(Iron destroys cartilage).\n**2. The Mixing Study (The Detective Test)**\nPTTê°€ ì—°ì¥ë˜ì—ˆì„ ë•Œ, ì´ê²Œ **\"ì¬ë£Œ ë¶€ì¡±(Deficiency)\"**ì¸ì§€ **\"ë°©í•´ê¾¼(Inhibitor)\"**ì¸ì§€ êµ¬ë³„í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤.\n- **Method:** í™˜ìì˜ í˜ˆì¥(Patient Plasma) + ì •ìƒ í˜ˆì¥(Normal Plasma)ì„ **50:50**ìœ¼ë¡œ ì„ìŒ.\n    - ì •ìƒ í˜ˆì¥ì—ëŠ” ëª¨ë“  ì¸ìê°€ 100% ë“¤ì–´ìˆìœ¼ë¯€ë¡œ, ì„ìœ¼ë©´ ìµœì†Œ 50%ì˜ ì¸ìê°€ í™•ë³´ë¨ (clotting í•˜ê¸°ì— ì¶©ë¶„í•¨).\n| **Scenario** | **Mixing Result** | **Interpretation** | **Diagnosis Example** |\n| --- | --- | --- | --- |\n| **A** | **Corrects (Normalizes)** | ë¶€ì¡±í•œ ì¬ë£Œê°€ ì±„ì›Œì ¸ì„œ í•´ê²°ë¨ | **Hemophilia A/B** (Factor Deficiency) |\n| **B** | **Does NOT Correct** | ì •ìƒ í˜ˆì¥ì„ ë„£ì–´ë„ ì—¬ì „íˆ ì‘ê³  ì•ˆ ë¨ | **Inhibitor** present (e.g., Lupus Anticoagulant) |\n---\n### H3: Lupus Anticoagulant - The Great Misnomer ğŸ­\n- **Name:** \"Anticoagulant\"ë¼ê³  ë¶€ë¥´ì§€ë§Œ ì‹¤ì œë¡œëŠ” ëª¸ ì•ˆì—ì„œ **Clotting (Hypercoagulable)**ì„ ìœ ë°œí•©ë‹ˆë‹¤. (Anti-phospholipid Syndrome).\n- **Laboratory Artifact:** í…ŒìŠ¤íŠ¸ íŠœë¸Œ(In vitro) ì•ˆì—ì„œëŠ” ì‹œì•½(Chemicals)ê³¼ ê²°í•©í•˜ì—¬ ë§ˆì¹˜ Inhibitorì²˜ëŸ¼ ì‘ìš©í•´ PTTë¥¼ ì—°ì¥ì‹œí‚µë‹ˆë‹¤.\n- **Confirmation:** **Russel Viper Venom Time** or adding excess phospholipids (Overwhelms the artifact).\n- **Result:** **Body = Clots (DVT/PE/Miscarriage)**, Lab = Bleeds (High PTT).\n---\n# H1: DIC (Disseminated Intravascular Coagulation) ğŸ“‰","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-224","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"### H2: The Consumer\n**Concept:** ì‘ê³  ì¸ìì™€ í˜ˆì†ŒíŒì„ ë¯¸ì¹œ ë“¯ì´ ì¨ë²„ë ¤ì„œ(Consumption) ë‚¨ëŠ” ê²Œ ì—†ëŠ” ìƒíƒœ.\n| **Type** | **Trigger** | **Presentation** | **Mechanism** |\n| --- | --- | --- | --- |\n| **Acute DIC** | Sepsis, Trauma, Obstetric complications | **Bleeding** from everywhere (IV sites, gums) | \"Flash Fire\" - Factors used up instantly. |\n| **Chronic DIC** | **Malignancy** (Cancer) | **Thrombosis** (DVT/PE) | Body compensates enough to stop bleeding but keeps clotting. |\n---\n# H1: Vitamin K & The Gut Flora Factory ğŸ¥¦ğŸ­\n- **Dependent Factors:** **2, 7, 9, 10**, Protein C, S.\n- **Source:** ë…¹ìƒ‰ ì±„ì†Œ(Leafy Greens) + **Gut Bacteria (ì¥ë‚´ ì„¸ê· )**.\n- **Antibiotic Connection:** ê´‘ë²”ìœ„ í•­ìƒì œ(Broad-spectrum Abx)ë¥¼ ì“°ë©´ ì¥ë‚´ ì„¸ê· (Factory workers)ì´ ì£½ìŠµë‹ˆë‹¤. â†’ Vitamin K ìƒì‚° ì¤‘ë‹¨ â†’ 7~10ì¼ ë’¤ ì¶œí˜ˆ ê²½í–¥(INR ìƒìŠ¹) ë°œìƒ.\n---\n# H1: Reversal Agents (The \"Undo\" Buttons) â†©ï¸ğŸ’Š\n| **Drug** | **Reversal Agent (Antidote)** | **Notes** |\n| --- | --- | --- |\n| **Warfarin** | **PCC (Prothrombin Complex Concentrate)** | Fastest! (Instant restock). Vit K is too slow. |\n| **Heparin** | **Protamine Sulfate** | Binds and neutralizes. |\n| **DOACs** | Andexanet alfa / Idarucizumab | Specific reversal agents exist now. |\n| **Platelet Anti-agents** | Platelet Transfusion | Usually just wait, but severe cases need platelets. |\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-244","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"recap_summary","text":"### âš¡ Rapid Fire Recap (High Yield)\n- **Schistocytes on smear** â†’ Think **MAHA** (TTP, HUS, DIC). ğŸ”ª\n- **TTP Pentad** â†’ Fever, Neuro sx, Renal, Anemia, Low Platelets. **Tx: Plasma Exchange**. (NO PLATELETS!). ğŸ©¸ğŸš«\n- **Kid + Bloody Diarrhea** â†’ **HUS**. **NO ANTIBIOTICS**. ğŸ”ğŸ’£\n- **Isolated Thrombocytopenia** â†’ **ITP**. Check **HIV/HCV**. ğŸ¦ \n- **Mixing Study Corrects** â†’ Factor Deficiency (Hemophilia). âœ…\n- **Mixing Study No Correction** â†’ Inhibitor (Lupus Anticoagulant). âŒ\n- **Deep Bleeding (Joints)** â†’ Factor problem. **Mucosal Bleeding** â†’ Platelet problem.\n---\n- ì˜¤ë””ì˜¤ì—ì„œëŠ” Mixing studyì—ì„œ Inhibitorê°€ ìˆì„ ë•Œ \"clotting time does not correct\"ë¼ê³  ëª…í™•íˆ ì„¤ëª…í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹¤ì œ ì„ìƒì—ì„œ Lupus Anticoagulant ë“±ì„ ì˜ì‹¬í•˜ëŠ” ê°•ë ¥í•œ ë‹¨ì„œì…ë‹ˆë‹¤.\n- \"Antibiotic Trap\" in HUS is a critical USMLE concept often tested. Do not confuse with treating standard sepsis.\n- Warfarin reversalì—ì„œ Vitamin KëŠ” íš¨ê³¼ê°€ ë‚˜íƒ€ë‚˜ê¸°ê¹Œì§€ ì‹œê°„ì´ ê±¸ë¦¬ë¯€ë¡œ(hours to days), ê¸‰í•œ ì¶œí˜ˆ(Acute Bleed)ì—ëŠ” ë°˜ë“œì‹œ **PCC (Factor replacement)**ë¥¼ ì¨ì•¼ í•œë‹¤ëŠ” ì ì„ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤.\n# 5.0-5.4 ğŸ“ Senior Medical Scribe & USMLE Expert Note: Hodgkin Lymphoma Survivorship & Complications\n## ğŸ“‹ TL;DR Overview (Executive Summary)\n- **Core Topic:** Hodgkin Lymphoma (HL) ìƒì¡´ìì˜ ì¥ê¸° í•©ë³‘ì¦ (Late Complications) ë° 2ì°¨ ì•” (Secondary Malignancy).\n- **Key Concept:** ì¹˜ë£Œ í›„ 15ë…„ì´ ì§€ë‚˜ë©´, ì›ë˜ì˜ ë¦¼í”„ì¢… ì¬ë°œ(Relapse)ë³´ë‹¤ **ì¹˜ë£Œ ë¶€ì‘ìš©ìœ¼ë¡œ ì¸í•œ 2ì°¨ ì•”(Secondary Malignancy)**ìœ¼ë¡œ ì‚¬ë§í•  í™•ë¥ ì´ ë” ë†’ìŒ.\n- **High Yield Traps:**\n    1. **Timeframe:** 5ë…„ ì´ë‚´ = Relapse / 15ë…„ ì´í›„ = Secondary Cancer.\n    2. **Cardio:** Radiation (Restrictive/CAD) vs. Doxorubicin (Dilated).\n    3. **Emergency:** Tumor Lysis Syndrome & G6PD deficiency contraindication for Rasburicase.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-254","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","treatment"]}
{"chunk_type":"transcript_chunk","text":"\"We are going to start right at the doorway today. I want you to picture a specific patient because this... uh... this clinical vignette is going to frame everything we discuss about oncology complications for Step 2. Itâ€™s the classic survivor scenario isnâ€™t it? It is. So youâ€™re in the clinic, a 42-year-old man walks in... You know, looks pretty good, but heâ€™s complaining of a new dry cough, some, you know, shortness of breath when he exercises, and this vague chest pain.\"\n---\n## ğŸŒ³ Top-Down Classification Tree (Big Picture)\nUSMLE ê´€ì ì—ì„œ Oncology ComplicationsëŠ” í¬ê²Œ **Time Course**ì™€ **Etiology**ë¡œ ë‚˜ë‰©ë‹ˆë‹¤.\nPlaintext\n`Complications of Cancer Therapy\nâ”œâ”€â”€ 1. Acute Emergencies (ì¹˜ë£Œ ì§í›„)\nâ”‚   â”œâ”€â”€ Tumor Lysis Syndrome (TLS)\nâ”‚   â”‚   â”œâ”€â”€ Hyperkalemia\nâ”‚   â”‚   â”œâ”€â”€ Hyperphosphatemia\nâ”‚   â”‚   â””â”€â”€ Hyperuricemia (-> Renal Failure)\nâ”‚   â””â”€â”€ Neutropenic Fever\nâ”‚\nâ””â”€â”€ 2. Late Effects / Survivorship (ì¹˜ë£Œ ìˆ˜ë…„~ìˆ˜ì‹­ë…„ í›„)\n    â”œâ”€â”€ Secondary Malignancies (ê°€ì¥ ì¤‘ìš” â˜…)\n    â”‚   â”œâ”€â”€ Solid Tumors (Radiation induced: Lung, Breast, Thyroid)\n    â”‚   â””â”€â”€ Hematologic (Chemo induced: AML, MDS)\n    â”‚\n    â”œâ”€â”€ Cardiovascular Disease\n    â”‚   â”œâ”€â”€ Chemotherapy (Doxorubicin -> DCM)\n    â”‚   â””â”€â”€ Radiation (Fibrosis -> RCM, CAD, Valve)\n    â”‚\n    â””â”€â”€ Endocrine/Pulmonary\n        â”œâ”€â”€ Hypothyroidism\n        â””â”€â”€ Pulmonary Fibrosis (Bleomycin, Radiation)`\n---\n## Step 3: \"Zero-Loss\" Lecture Notes ğŸš€\n### 1. The Clinical Vignette: The \"Doorway\" Thought ğŸšª\n- **Patient:** 42ì„¸ ë‚¨ì„±.\n- **History:** 20ëŒ€ ì´ˆë°˜ì— Hodgkin Lymphoma (HL) ì§„ë‹¨. Chemo (ABVD) + Mantle Field Radiation ë°›ìŒ. 20ë…„ê°„ ê´€í•´(Remission) ìƒíƒœ.\n- **Presenting Complaint:** New dry cough, Dyspnea on exertion (SOB), Vague chest pain.\n- **The Clinical Trap:**\n    - ì¦ìƒë§Œ ë³´ë©´ Respiratory Infection (Bronchitis) í˜¹ì€ Lymphoma Relapseë¥¼ ì˜ì‹¬í•˜ê¸° ì‰¬ì›€.\n    - **BUT:** Historyê°€ ëª¨ë“  ê²ƒì„ ê²°ì •í•¨ (Context is King).\n    - ë§Œì•½ ì¹˜ë£Œ í›„ **2ë…„** ì§€ë‚¬ë‹¤ë©´? â†’ **Relapse**ê°€ 1ìˆœìœ„.\n    - ë§Œì•½ ì¹˜ë£Œ í›„ **20ë…„** ì§€ë‚¬ë‹¤ë©´? â†’ **Secondary Malignancy** (Solid tumor)ê°€ 1ìˆœìœ„.\n### 2. The Survivorship Paradox (Survivorship & Risk) ğŸ“ˆ\nHodgkin'sëŠ” í˜„ëŒ€ ì˜í•™ì˜ ìŠ¹ë¦¬(Cure rate > 75~90%)ì´ì§€ë§Œ, ê·¸ ëŒ€ê°€ê°€ ë”°ë¦…ë‹ˆë‹¤.\n- **ì¶©ê²©ì ì¸ í†µê³„ (The Scary Stat):** ì¼ë°˜ì¸ ëŒ€ë¹„ 2ì°¨ ì•” ë°œìƒ ìœ„í—˜ì´ **18.5ë°°(18.5-fold)** ì¦ê°€í•¨.\n- **The \"Cross-Over\" Point:**\n    - ì¹˜ë£Œ í›„ 15ë…„ ì‹œì (15-year mark)ì„ ê¸°ì ìœ¼ë¡œ, ì‚¬ë§ ì›ì¸ 1ìœ„ê°€ HL ì¬ë°œì´ ì•„ë‹ˆë¼ **Secondary Malignancy**ë¡œ ì—­ì „ë¨.\n### 3. Radiation vs. Chemotherapy Risks (The Rules) â˜¢ï¸ vs ğŸ’Š\nì–´ë–¤ ì¹˜ë£Œë¥¼ ë°›ì•˜ëŠëƒì— ë”°ë¼ ë°œìƒí•˜ëŠ” ì•”ì˜ ì¢…ë¥˜ì™€ ì‹œê¸°ê°€ ë‹¤ë¦…ë‹ˆë‹¤.\n| **Feature** | **Radiation Therapy (Local Beam)** | **Chemotherapy (Systemic, Alkylating)** |\n| --- | --- | --- |\n| **Mechanism** | DNA Damage in specific field | Systemic DNA damage |\n| **Type of Cancer** | **Solid Tumors** (ê³ í˜•ì•”) | **Hematologic Malignancies** (í˜ˆì•¡ì•”) |\n| **Target Organs** | **Lung** (esp. smokers), **Breast**, Thyroid, Bone, Skin | Bone Marrow (AML, MDS) |\n| **Latency (ì ë³µê¸°)** | **Long** (10~30ë…„ ì´ìƒ, ìœ„í—˜ë„ ê³„ì† ìƒìŠ¹) | **Short** (5~10ë…„ í›„ Peak, ì´í›„ ê°ì†Œ) |\n| **Special Note** | ì Šì€ ì—¬ì„±ì˜ Chest Radiation = BRCA mutationê¸‰ ìœ ë°©ì•” ë¦¬ìŠ¤í¬ | Acute Myeloid Leukemia (AML) ìœ„í—˜ ê¸‰ì¦ |\n### 4. Cardiovascular Toxicity: The Silent Killer ğŸ’”","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-264","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"í™˜ìì˜ \"Cough & SOB\"ëŠ” íì•”ì¼ ìˆ˜ë„ ìˆì§€ë§Œ, ì‹¬ì¥ ë¬¸ì œì¼ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤.\n- **Radiation Induced Heart Disease:**\n    - *Fibrosis(ì„¬ìœ í™”)**ê°€ í•µì‹¬ ê¸°ì „.\n    - Coronary Artery Disease (CAD): í˜ˆê´€ì´ ë”±ë”±í•´ì§ -> Premature MI.\n    - Valvular Disease: íŒë§‰ì´ êµ³ìŒ (Stenosis/Regurgitation).\n    - **Restrictive Cardiomyopathy (RCM):** ì‹¬ê·¼ê³¼ ì‹¬ë‚­(Pericardium)ì´ êµ³ì–´ì„œ ì´ì™„ì´ ì•ˆ ë¨ (Pericardial constriction).\n- **Chemotherapy (Anthracyclines - Doxorubicin):**\n    - AKA \"The Red Devil\".\n    - **Dilated Cardiomyopathy (DCM):** ì‹¬ì¥ì´ í—ê±°ì›Œì§€ê³  ëŠ˜ì–´ë‚¨. Dose-dependent (í‰ìƒ ëˆ„ì  ìš©ëŸ‰ ì¤‘ìš”).\n- **Actionable Step:**\n    - â˜… **Next Best Step:** **Echocardiogram** (Lung workupê³¼ ë™ì‹œì— ì‹¬ì¥ ê¸°ëŠ¥ í‰ê°€ í•„ìˆ˜).\n### 5. High-Yield Diagnostic Traps (ì‹œí—˜ì— ë‚˜ì˜¤ëŠ” í•¨ì •ë“¤) ğŸª¤\n### A. The Alcohol Sign (Lymphoma Specific) ğŸº\n- í™˜ìê°€ \"ìˆ ì„ í•œ ëª¨ê¸ˆ ë§ˆì…¨ë”ë‹ˆ ë¦¼í”„ì ˆ ë¶€ìœ„ê°€ ì°¢ì–´ì§€ê²Œ ì•„í”„ë‹¤\"ê³  í•¨.\n- ì´ê²ƒì€ Hodgkin Lymphomaì˜ **Pathognomonic Sign** (íŠ¹ì´ì  ì§•í›„).\n- ê¸°ì „ì€ ë¶ˆëª…í™•í•˜ì§€ë§Œ, ë¦¼í”„ì ˆ ë‚´ í˜ˆê´€ í™•ì¥ê³¼ ìº¡ìŠ íŒ½ì°½(Capsule stretch)ìœ¼ë¡œ ì¶”ì •.\n### B. The Bone Scan Trap (Multiple Myeloma Contrast) â˜ ï¸\nì´ê²ƒì€ Hodgkin ì´ì•¼ê¸°ëŠ” ì•„ë‹ˆì§€ë§Œ, ì¢…ì–‘í•™ Imagingì˜ í•µì‹¬ í•¨ì •ìœ¼ë¡œ ì–¸ê¸‰ë¨.\n- **Scenario:** ë…¸ì¸, í—ˆë¦¬ í†µì¦(Back pain), Anemia, Hypercalcemia. -> Multiple Myeloma(MM) ì˜ì‹¬.\n- **Trap:** \"Bone Scan\" (Technetium-99m)ì„ ì˜¤ë”í•˜ë©´ ì•ˆ ë¨.\n- **Reasoning:**\n    - Bone Scanì€ Osteoblast(ì¡°ê³¨ì„¸í¬/ë¼ˆ ìƒì„±) activityë¥¼ ë´„.\n    - Multiple MyelomaëŠ” ìˆœìˆ˜í•˜ê²Œ **Osteolytic** (íŒŒê³¨/ë¼ˆ íŒŒê´´) processì„. (Construction crew is on strike, Demolition crew is active).\n    - ë”°ë¼ì„œ MM í™˜ìëŠ” **Bone Scanì—ì„œ ì •ìƒ(Cold)**ìœ¼ë¡œ ë‚˜ì˜´ (False Negative).\n- â˜… **Gold Standard for MM Bone Survey:**\n    - **Skeletal Survey (X-ray series)** (Punched-out lytic lesions í™•ì¸).\n    - ìµœê·¼ íŠ¸ë Œë“œëŠ” **Low-dose Whole Body CT**ê°€ ë” ë¯¼ê°í•¨.\n### 6. Acute Emergency: Tumor Lysis Syndrome (TLS) ğŸ’¥\nì¹˜ë£Œ ì‹œì‘ ì§í›„ ë°œìƒí•˜ëŠ” ì‘ê¸‰ ìƒí™© (Act 2ì˜ ìœ„ê¸°).\n- **Pathophysiology:**\n    - Chemoê°€ íš¨ê³¼ê°€ ì¢‹ì•„ì„œ ì•”ì„¸í¬ê°€ ëŒ€ëŸ‰ìœ¼ë¡œ í„°ì§.\n    - ì„¸í¬ ë‚´ìš©ë¬¼ ë°©ì¶œ: Potassium (K+), Phosphate (PO4), Uric Acid (DNA breakdown).\n- **Consequence:**\n    - High K+ -> Arrhythmia.\n    - High Uric Acid -> Urate Crystals -> **Acute Renal Failure** (Renal tubules ë§‰í˜).\n- **Pharmacology Twist (Step 2 Killer Q):**\n    - **Prevention:** Allopurinol (Xanthine Oxidase Inhibitor) - ìƒˆë¡œìš´ Uric acid ìƒì„± ì–µì œ.\n    - **Treatment (Active):** **Rasburicase** (Urate Oxidase analog).\n        - ì´ë¯¸ ë§Œë“¤ì–´ì§„ Uric acidë¥¼ ë¬¼ì— ì˜ ë…¹ëŠ” Allantoinìœ¼ë¡œ ë¶„í•´í•´ë²„ë¦¼ (Pac-Manì²˜ëŸ¼ ë¨¹ì–´ì¹˜ì›€).\n    - **â›” CONTRAINDICATION (Rasburicase):**\n        - **G6PD Deficiency í™˜ì.**\n        - RasburicaseëŠ” Uric acidë¥¼ ë¶„í•´í•  ë•Œ **Hydrogen Peroxide (H2O2)**ë¥¼ ë¶€ì‚°ë¬¼ë¡œ ë§Œë“¦.\n        - G6PD ê²°í• í™˜ìì˜ ì í˜ˆêµ¬ëŠ” Oxidative stress(H2O2)ë¥¼ ëª» ê²¬ë”¤ -> **Massive Hemolysis** (Dark urine, Jaundice, Bite cells) ë°œìƒ.\n        - G6PD ê²°í•ì´ ì˜ì‹¬ë˜ëŠ” í™˜ìêµ°(African, Mediterranean, Asian descent)ì—ê²ŒëŠ” ì¹˜ëª…ì ì¼ ìˆ˜ ìˆìŒ.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-284","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"## âš¡ Rapid Fire Recap (High Yield Associations)\n| **Clinical Scenario** | **Suspected Diagnosis / Mechanism** | **Next Step / Key Fact** |\n| --- | --- | --- |\n| **Hodgkin survivor, 20 yrs later, Cough/SOB** | **Secondary Lung Cancer** (esp. if smoker) | CT Chest (Low dose screening) |\n| **Young female, Chest Radiation history** | **Secondary Breast Cancer** | MRI Breast Screening starts 8-10 yrs post-tx |\n| **Doxorubicin history + SOB** | **Dilated Cardiomyopathy** | Echocardiogram |\n| **Radiation history + R-sided Heart Failure** | **Restrictive Cardiomyopathy / Pericarditis** | Echocardiogram (Stiff heart) |\n| **Pain in lymph node after Alcohol** | **Hodgkin Lymphoma** (Recurrence/Dx) | Pathognomonic Sign |\n| **Multiple Myeloma suspected + Bone Pain** | Lytic Lesions | **Skeletal Survey (X-ray)** or CT. NO Bone Scan! |\n| **Tumor Lysis + Dark Urine after Rasburicase** | **G6PD Deficiency Hemolysis** | Stop drug, Support. |\n---\n## ğŸ“ Next Step for You\nWould you like me to generate a **USMLE-style multiple-choice question (vignette)** based on the \"Rasburicase vs. G6PD\" trap to test your understanding?\n# 4.0-4.5 ğŸ“‹ Overview: Hematology Crisis Management (TL;DR)\n**Clinical Context:** ì˜¤ëŠ˜ ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ êµê³¼ì„œì ì¸ Pathwayê°€ ì•„ë‹ˆë¼, í™˜ìì˜ ìƒì‚¬ê°€ ì˜¤ê°€ëŠ” **Crisis Management**ì— ëŒ€í•´ ë‹¤ë£¹ë‹ˆë‹¤. ëª¸ì˜ í•­ìƒì„±(Homeostasis)ì´ ì™„ì „íˆ ë¬´ë„ˆì§„ ìˆœê°„, ìš°ë¦¬ëŠ” ì–´ë–»ê²Œ ê°œì…í•´ì•¼ í• ê¹Œìš”?\n- **ğŸ©¸ Warfarin Reversal:** \"ê³µì¥(Liver)\"ì„ ê³ ì¹  ì‹œê°„ì´ ì—†ì„ ë•Œ, \"ì™„ì œí’ˆ(PCC)\"ì„ íˆ¬í•˜í•˜ë¼.\n- **ğŸ’Š DOAC Reversal:** 1:1 ë§¤ì¹­ ê²Œì„ (Andexanet alfa & Idarucizumab).\n- **ğŸ¤° Pregnancy:** íƒœë°˜ì„ í†µê³¼í•˜ì§€ ì•ŠëŠ” Heparin ì „ëµê³¼ ì¶œì‚° ì§ì „ì˜ \"Switching\".\n- **ğŸ“‰ HIT (Heparin Induced Thrombocytopenia):** í”¼ê°€ ë¬½ì–´ì§€ëŠ” ìˆ˜ì¹˜(Low Plt)ì¸ë° í”¼ê°€ êµ³ëŠ”(Clotting) ì—­ì„¤. **Don't give Platelets!**\n- **ğŸˆ EPO Side Effect:** í”¼ê°€ ì§„í•´ì§€ë©´ì„œ ë°œìƒí•˜ëŠ” Severe Hypertension.\n- **ğŸ‘¶ Kasabach-Merritt:** ê±°ëŒ€ ì¢…ì–‘ì´ í˜ˆì†ŒíŒì„ \"Sponge\"ì²˜ëŸ¼ ë¹¨ì•„ë“¤ì´ëŠ” ì†Œì•„ ì‘ê¸‰.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-296","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","treatment","pathophysiology"]}
